テキサスにおける骨髄増殖性腫瘍の臨床試験
テキサス内の拠点で、骨髄増殖性腫瘍に関する18件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- The University of Texas, MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07469891Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
被験者募集中第1相
1歳以上 · 全性別 · 2026/09/18更新 · NCT03630991(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03471260CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT04493164Project: Every Child for Younger Patients With Cancer
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他12件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07441694Asciminib Roll-over Study
- Texas Oncology, Dallas
- Uni Of TX MD Anderson Cancer Cntr, Houston
被験者募集中第4相
7歳〜100歳 · 全性別 · 2026/07/06更新 · NCT04877522Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- M D Anderson Cancer Center, Houston
被験者募集中第2相
12歳以上 · 全性別 · 2026/05/22更新 · NCT03589729A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Md Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/17更新 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
被験者募集中
18歳以上 · 全性別 · 2026/02/20更新 · NCT05745285SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/13更新 · NCT05423691ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。